INBX

Inhibrx Biosciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-19

Figures on this page computed 2026-11-08 13:05 UTC

Last close

86.76USD

Market data, 2026-11-04

INBX: weekly closes from 80.69 on 2025-11-07 to 86.76 on 2026-11-04, a move of +7.5%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: +7.5%

Except where said otherwise: 10-K for 2025, filed 2026-03-19

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-19
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
-10773.5%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
-9986.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
13.39Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.08 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.22x

-1.57x

1.50x

1.47x

2.52x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-19

Sales0.22x
Its own average over 10 years, 5.8M.
Profit-1.57x
Its own average over 10 years, 89.3M.
Free cash flow1.50x
Its own average over 10 years, -86.8M.
Debt1.47x
Its own average over 10 years, 72.7M.
Price2.52x
Its own average over 7 years, 34. Market data, 2026-11-04

Profit is furthest from its own average, at -1.57 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	100.0
2017-12-31	125.9	78.8
2018-12-31	128.9	74.1
2019-12-31	136.4	100.0
2020-12-31	192.1	69.1
2021-12-31	106.9	104.0
2022-12-31	32.9	109.7
2023-12-31	27.0	32.2
2024-12-31	3.0	41.0
2025-12-31	19.5	42.4

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0002007919-26-000006
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0002007919-26-000006
Reported in: USD

The filing itself

Figures behind the shape

Growth

-36.7%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate-36.7%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-108.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-1752.2%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on equity-1752.2%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on assets-95.6%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself

Margins

-10386.5%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
Operating margin-10386.5%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
Net margin-10773.5%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
Free cash flow margin-9986.5%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself

Price

163.8x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-19
The filing itself
Price to book163.8x10-Q for 2025, filed 2026-08-13
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0002007919-26-000042
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-13
- computed
- 10-K for 2025, filed 2026-03-19
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-19
The filing itself
Price to sales ratio1006.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself

Safety

13.39

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity13.39
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
Current ratio3.9310-Q for 2025, filed 2026-08-13
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0002007919-26-000042
Reported in
USD
- 10-Q for 2025, filed 2026-08-13
- 10-Q for 2025, filed 2026-08-13
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
Altman Z-Score1.10
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-19
- Computed from the 10-K for 2025, filed 2026-03-19
- Computed from the 10-K for 2025, filed 2026-03-19
- Computed from the 10-K for 2025, filed 2026-03-19
- Computed from the 10-K for 2025, filed 2026-03-19

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- Computed from the 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.